Sweet's syndrome after adalimumab therapy for refractory relapsing polychondritis.
Relapsing polychondritis and Sweet's syndrome are rare systemic inflammatory conditions. The authors present a patient who developed Sweet's syndrome 1 week after adalimumab therapy for refractory relapsing polychondritis. Coexistent relapsing polychondritis and Sweet's syndrome is rare, however, is likely to represent a true disease association and signifies a high risk of myelodysplasia. Antitumour necrosis factor α (TNFα) therapy is a treatment option in both relapsing polychondritis and Sweet's syndrome, and switching anti-TNFα agents may be feasible in the event of adverse reaction.
Department of Rheumatology, Stoke Mandeville Hospital, Aylesbury, UK. sarahk27@yahoo.com
Sarah
S
Keidel
Aubretia
A
McColl
Sally
S
Edmonds
D000068879:Adalimumab; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D011081:Polychondritis, Relapsing / Q000188:drug therapy*; D016463:Sweet Syndrome / Q000139:chemically induced*
D000893:Anti-Inflammatory Agents; D061067:Antibodies, Monoclonal, Humanized; D000068879:Adalimumab